modelTolvaptan_Lanke2019_base

Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral.

Information

name:tolvaptan
ATC code:C03XA01
model:one compartment, oral dosing (PK_1C_enteral)
source:Lanke S et al. 2019
population:adults with autosomal dominant polycystic kidney disease
measured compound:tolvaptan
review:curated candidate
record page:pharmacolibrary-docs

Parameters as reported in the paper

parametervalueunitmeaning
CL/F (L/h)11.4L/hCL/F
Vd/F (L)109LV/F
D1 (h)0.55hD1
k a (h -1 )1.34h -1kabs

About tolvaptan

Tolvaptan is a vasopressin receptor antagonist used to treat low blood sodium (hyponatremia) linked to heart failure, cirrhosis, or inappropriate antidiuretic hormone secretion, and is also authorised for autosomal dominant polycystic kidney disease. It remains in use, with authorised products in the European Union, though it carries a boxed warning.

Summary written by glm-5.3-flash from Wikidata Q426132 and the WHO ATC classification and the EMA medicines list; not checked by a person.

Identity, molar mass and metabolites: Tolvaptan.

References

  1. Lanke S et al. (2019). Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. Journal of clinical pharmacology 59(5):763–770. DOI:10.1002/jcph.1370 PUBMED:30618157

Parameters

TypeNameDefaultDescription
RealCl_ref3.1666666666666667e-06Cl [m3/s]
RealVd_ref0.109Vd [m3]
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.0009Volume of distribution per kg (default 0.9 L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)1bioavailability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)2.7777777777777776e-7clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1e-4administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)
Info › Therapeutic range (metadata, not used in equations)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008maximal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Info › Substance metadata
Modelica.Units.SI.MolarMassMM (from PK_1C)0molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0)
Info › Substance metadata (not used in equations)
Pharmacolibrary.Types.DoseLD50 (from PK_1C)0median lethal dose [mg/kg]; 0 = unknown

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models)

Revisions

  • 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Lanke_2019: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: curated candidate